The US FDA has approved individual exploratory treatment for COVID-19 infections in which a patient may be eligible to receive convalescent plasma under single-patient emergency Investigational New Drug Applications.
“This process allows the use of an investigational drug for the treatment of an individual patient by a licensed physician upon FDA authorisation. This does not include the use of COVID-19 convalescent plasma for the prevention of infection,” the FDA said.
COVID-19 convalescent plasma must only be collected from recovered individuals if they are eligible to donate blood. Required testing must be performed and the donation must be found suitable, the agency added.